Abstract
Objective. The B cell chemoattractant chemokine ligand 13 (CXCL13) is emerging as a new biochemical marker in RA. This study was undertaken to dissect the relationship between CXCL13 expression levels in the synovium and clinico-pathological variables relevant to RA pathogenesis and outcome. Methods. Synovial tissues from 71 RA patients were evaluated by immunohistochemistry. Thirty paired samples were used for comparative gene expression analysis by quantitative real-time PCR. CXCL13 levels were analysed in relation to cellular, molecular and clinical features of inflammation, lymphocyte activation and joint damage. Results. In patients with early disease (
Original language | English |
---|---|
Pages (from-to) | 1886-1895 |
Number of pages | 10 |
Journal | Rheumatology |
Volume | 53 |
Issue number | 10 |
DOIs | |
Publication status | Published - Oct 1 2014 |
Keywords
- B lymphocytes
- Biomarkers
- CXCL13
- Rheumatoid arthritis
- Synovium
ASJC Scopus subject areas
- Rheumatology
- Pharmacology (medical)